Aurora Cannabis Inc. (NASDAQ: ACB) reported its financial and operational results for the fourth quarter and fiscal year ending June 30, 2022, on Tuesday, revealing a net revenue of $50.2 million compared to the previous quarter's total cannabis net revenue of $50.4 million.

Medical cannabis net revenue totaled $36.6 million, representing a 4% increase from the prior year period and accounting for 72.8% of Aurora's quarterly consolidated net revenue.

The Canadian cannabis giant attributed the increase in revenue to the international medical business, which was up 35.4% compared to last year, as Aurora continues to strengthen its presence in key emerging international medical cannabis markets.

Cantor Fitzgerald's analyst Pablo Zuanic said in his recent note that Aurora is …

Full story available on Benzinga.com